Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
| ▸ | FPR3 | P25089 | 1/20 | 0.46 |
| ▸ | FPR2 | P25090 | 1/20 | 0.46 |
| ▸ | GLS | O94925 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31117959 | 0.87 | KDM4E (0.60) | KDM4EPKMEPHX1TGFBR1SMN1; SMN2 | |
| SCHEMBL3050761 | 0.87 | KDM4E (0.60) | KDM4EPKMEPHX1TGFBR1SMN1; SMN2 | |
| SCHEMBL21551436 | 0.87 | KDM4E (0.63) | KDM4EPKMEPHX1SMN1; SMN2HPGD | |
| SCHEMBL6402066 | 0.86 | KDM4E (0.59) | KDM4EPKMEPHX1TGFBR1SMN1; SMN2 | |
| SCHEMBL18980843 | 0.85 | KDM4E (0.56) | KDM4EPKMEPHX1TGFBR1SMN1; SMN2 | |
| SCHEMBL24853346 | 0.85 | KDM4E (0.64) | KDM4EPKMEPHX1TGFBR1SMN1; SMN2 | |
| SCHEMBL1245476 | 0.85 | KDM4E (0.64) | KDM4EPKMEPHX1TGFBR1SMN1; SMN2 | |
| SCHEMBL6152939 | 0.85 | KDM4E (0.68) | KDM4EPKMEPHX1TGFBR1SMN1; SMN2 | |
| SCHEMBL6150181 | 0.85 | KDM4E (0.58) | KDM4EPKMEPHX1TGFBR1HPGD | |
| SCHEMBL5573225 | 0.85 | KDM4E (0.63) | KDM4EPKMEPHX1TGFBR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739174-B2 | Cationic cyclic amine and amphipathic transfection reagents | MIRUS BIO LLC (US) | 2023-08-29 | — | — | US | disclosed |
| US-20100234427-A1 | 1-PHENETHYLPIPERIDINE DERIVATIVES AND THEIR USE AS OPIOID RECEPTOR LIGANDS | NEUROSEARCH A/S (DK) | 2010-09-16 | — | — | US | disclosed |
| EP-1987001-B1 | 1-PHENETHYLPIPERIDINE DERIVATIVES AND THEIR USE AS OPIOID RECEPTOR LIGANDS | NEUROSEARCH AS (DK) | 2010-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234427-A1 | 1-PHENETHYLPIPERIDINE DERIVATIVES AND THEIR USE AS OPIOID RECEPTOR LIGANDS | OPRL1, OPRM1, OPRK1 | KDM4E 622/4885PKM 1707/4885EPHX1 619/4885 |
| US-11739174-B2 | Cationic cyclic amine and amphipathic transfection reagents | SLC7A1, PARN, PARG | KDM4E 4494/4885PKM 2772/4885EPHX1 4508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.